N.sup.4-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses

A diverse group of RNA viruses have the ability to gain access to the central nervous system (CNS) and cause severe neurological disease. Current treatment for people with this type of infection is generally limited to supportive care. To address the need for reliable antivirals, we utilized a strat...

Full description

Saved in:
Bibliographic Details
Published in:PLoS pathogens 2024-09, Vol.20 (9), p.e1012574
Main Authors: Ojha, Durbadal, Hill, Collin S, Zhou, Shuntai, Evans, Alyssa, Leung, Jacqueline M, Schneider, Christine A, Amblard, Franck, Woods, Tyson A, Schinazi, Raymond F, Baric, Ralph S, Peterson, Karin E, Swanstrom, Ronald
Format: Article
Language:English
Subjects:
Analysis
Development and progression
Drug therapy
Encephalitis
Medical research
Medicine, Experimental
Nervous system diseases
Neurons
Paralysis
Pharmacology, Experimental
Physiological aspects
RNA
RNA viruses
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A diverse group of RNA viruses have the ability to gain access to the central nervous system (CNS) and cause severe neurological disease. Current treatment for people with this type of infection is generally limited to supportive care. To address the need for reliable antivirals, we utilized a strategy of lethal mutagenesis to limit virus replication. We evaluated ribavirin (RBV), favipiravir (FAV) and N.sup.4 -hydroxycytidine (NHC) against La Crosse virus (LACV), which is one of the most common causes of pediatric arboviral encephalitis cases in North America and serves as a model for viral CNS invasion during acute infection. NHC was approximately 3 to 170 times more potent than RBV or FAV in neuronal cells. Oral administration of molnupiravir (MOV), the prodrug of NHC, decreased neurological disease development (assessed as limb paralysis, ataxia and weakness, repeated seizures, or death) by 31% (4 mice survived out of 13) when treatment was started on the day of infection. MOV also reduced disease by 23% when virus was administered intranasally (IN). NHC and MOV produced less fit viruses by incorporating predominantly G to A or C to U mutations. Furthermore, NHC also inhibited virus production of two other orthobunyaviruses, Jamestown Canyon virus and Cache Valley virus. Collectively, these studies indicate that NHC/MOV has therapeutic potential to inhibit viral replication and subsequent neurological disease caused by orthobunyaviruses and potentially as a generalizable strategy for treating acute viral encephalitis.
ISSN:1553-7366
DOI:10.1371/journal.ppat.1012574